US court rejects Jazz attempt to revive Xyrem patents

The US Court of Appeals for the Federal Circuit has rejected Jazz Pharmaceuticals’ attempt to revive patents covering its narcolepsy drug Xyrem (sodium oxybate).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Jazz Pharmaceuticals acquires UK medical cannabis firm for $7.2bn

4 February 2021 Jazz Pharmaceuticals has acquired UK medicinal cannabis company GW Pharmaceuticals in a takeover worth $7.2 billion.

Americas

Hikma enters settlement agreement with Jazz to sell Xyrem generic

7 April 2017 Hikma Pharmaceuticals has entered into a settlement agreement with Jazz Pharmaceuticals, following a patent infringement dispute related to Jazz’s drug Xyrem.

Americas

Jazz plays on as Xyrem challenges quashed

15 January 2015 The US Patent and Trademark Office has rejected several petitions that challenged a patent covering Jazz Pharmaceuticals’ narcolepsy drug Xyrem (sodium oxybate).

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

US court rejects Jazz attempt to revive Xyrem patents

More on this story

Editor's picks

Editor's picks

More features